The Board has adopted a progressive dividend policy, intending to maintain or grow the dividend each year but, recognising that some earnings fluctuations are to be expected, the annual dividend will reflect the Board’s view of the earnings prospects over the entirety of the investment cycle.
The Board’s aim is to continue to strike a balance between the interests of the business, financial creditors and the Company’s shareholders. After providing for investment in the business, supporting the progressive dividend policy and maintaining a strong, investment-grade credit rating, the Board will keep under review potential investment in immediately earnings-accretive, value-enhancing opportunities.
Announcement & payment of dividends
2020欧洲杯体育足球滚球比分Dividends will normally be paid twice a year, with a greater proportion paid as a second interim.
- First interim: announced with second quarter and half year results and paid in September
- Second interim: announced with fourth quarter and full year results and paid in March
Dividend calculator & history
To calculate the value of your forthcoming/latest dividend payment, or to look-up previous payments, please use the dividend calculator.
Exchange rates used to convert dividend payments, announced in USD, GBP and SEK are based on the rates on the day prior to the dividend announcement.
Please refer to the dividend FAQ2020欧洲杯体育足球滚球比分 for common questions regarding dividend payments.
Most recent dividend announcement
2020欧洲杯体育足球滚球比分The second interim dividend 2019 announced on Friday 14 February 2020.
2020欧洲杯体育足球滚球比分Ex dividend date (Ordinary Shares & American Depositary Shares)
27 February 2020
2020欧洲杯体育足球滚球比分28 February 2020
30 March 2020
*For holders of American Depositary Shares (ADSs) this equates to $0.95 per ADS.
2020欧洲杯体育足球滚球比分Following the ratio change to the Company’s NYSE-listed sponsored Level 2 American Depositary Receipt programme on 27 July 2015, two ADSs equal one Ordinary Share.
Our Annual Report provides a wide range of information about our global business.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development
Answers to frequently asked shareholder questions.